Cross-section Band Ligation Versus Stepladder Band Ligation of Esophageal Varices

Launched by TANTA UNIVERSITY · Mar 11, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different techniques for treating esophageal varices, which are enlarged veins in the esophagus that can occur in patients with liver disease. The study aims to compare the "cross-section band ligation" technique with the "stepladder band ligation" technique to see which one is more effective in preventing complications, such as bleeding, and to check for any side effects. Participants will undergo a series of exams and procedures, including endoscopies, to assess their condition and receive treatment every two to four weeks until the varices are gone. After treatment, they will have follow-up visits to monitor for any recurrence of varices and evaluate their overall health.

To be eligible for this trial, participants should be over 18 years old, have liver cirrhosis, and show signs of medium to large esophageal varices. Certain individuals, such as those with a history of bleeding from varices, those on specific medications, or those with severe heart or lung conditions, cannot participate. Throughout the trial, participants can expect regular check-ups to monitor their health, as well as support and guidance from the research team. This trial is currently recruiting participants, and it provides an opportunity to contribute to important research that could improve treatment for patients with esophageal varices.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged \>18 years.
• • Cirrhotic patients.
• • Endoscopic evidence of medium/large-sized esophageal varices.
• Exclusion Criteria:
• • History of variceal bleeding or previous primary prevention of varices.
• • Portal vein thrombosis or previous porto-systemic shunts as TIPS.
• • Patients on drugs affecting portal pressure (beta blockers, nitrates).
• • Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, and severe bradycardia.
• • Patients with severe respiratory diseases (COPD, bronchial asthma).
• • Uncontrolled diabetes mellitus.
• • Renal impairment.
• • Hepatocellular carcinoma.
• • Allergy to carvedilol.
• • Pregnancy or lactation.